Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device
Neurocrine Biosciences (NBIX) has appointed Andrew Ratz, Ph.D. as Senior Vice President of Drug Development, Delivery and Device. Dr. Ratz will lead the transformation of Neurocrine's Chemistry, Manufacturing and Controls organization to support the company's expanding R&D portfolio.
Dr. Ratz joins Neurocrine following a 28-year tenure at Eli Lilly, where he contributed to developing and registering over 25 products across multiple therapeutic areas. His most recent role was Senior Vice President and Head of Drug Delivery, Device and Connected Solutions, where he led the integrated design of devices, drug-device combination products, and packaging systems. He previously served as Senior Director of Process Chemistry and Chemical Engineering and Head of Global Outsourcing for Lilly's small molecule portfolio.
Neurocrine Biosciences (NBIX) ha nominato Andrew Ratz, Ph.D. come Vice Presidente Senior dello Sviluppo Farmaceutico, Consegna e Dispositivi. Il Dott. Ratz guiderà la trasformazione dell'organizzazione di Chimica, Manifattura e Controlli di Neurocrine per supportare l'espansione del portafoglio R&D dell'azienda.
Il Dott. Ratz entra in Neurocrine dopo un'esperienza di 28 anni in Eli Lilly, dove ha contribuito allo sviluppo e alla registrazione di oltre 25 prodotti in diverse aree terapeutiche. Il suo ruolo più recente è stato quello di Vice Presidente Senior e Capo della Consegna Farmaceutica, Dispositivi e Soluzioni Connesse, dove ha guidato il design integrato di dispositivi, prodotti combinati farmaco-dispositivo e sistemi di imballaggio. In precedenza, ha ricoperto il ruolo di Direttore Senior della Chimica dei Processi e Ingegneria Chimica e Capo del Global Outsourcing per il portafoglio di piccole molecole di Lilly.
Neurocrine Biosciences (NBIX) ha nombrado a Andrew Ratz, Ph.D. como Vicepresidente Senior de Desarrollo Farmacéutico, Entrega y Dispositivos. El Dr. Ratz liderará la transformación de la organización de Química, Manufactura y Control de Neurocrine para apoyar el creciente portafolio de I+D de la empresa.
El Dr. Ratz se une a Neurocrine tras una carrera de 28 años en Eli Lilly, donde contribuyó al desarrollo y registro de más de 25 productos en múltiples áreas terapéuticas. Su rol más reciente fue Vicepresidente Senior y Jefe de Entrega de Medicamentos, Dispositivos y Soluciones Conectadas, donde lideró el diseño integrado de dispositivos, productos combinados de medicamentos y dispositivos, así como sistemas de empaque. Anteriormente, fue Director Senior de Química de Procesos e Ingeniería Química y Jefe de Global Outsourcing para el portafolio de pequeñas moléculas de Lilly.
Neurocrine Biosciences (NBIX)는 Andrew Ratz, Ph.D.를 의약품 개발, 전달 및 장치의 수석 부사장으로 임명했습니다. Ratz 박사는 Neurocrine의 화학, 제조 및 품질 관리 조직의 변화를 이끌어 회사의 연구 개발 포트폴리오 확장을 지원할 것입니다.
Ratz 박사는 Eli Lilly에서 28년의 경력을 쌓고 Neurocrine에 합류했습니다. 그는 여러 치료 분야에 걸쳐 25개 이상의 제품의 개발 및 등록에 기여했습니다. 그의 최근 역할은 의약품 전달, 장치 및 연결된 솔루션의 수석 부사장 겸 책임자로, 장치, 의약품-장치 조합 제품 및 포장 시스템의 통합 설계를 이끌었습니다. 이전에는 Lilly의 소분자 포트폴리오를 위한 공정 화학 및 화학 공학의 수석 이사이자 글로벌 아웃소싱 책임자를 역임했습니다.
Neurocrine Biosciences (NBIX) a nommé Andrew Ratz, Ph.D. au poste de Vice-Président Senior du Développement, de la Distribution et des Dispositifs Médicaux. Dr. Ratz dirigera la transformation de l'organisation Chimie, Fabrication et Contrôles de Neurocrine pour soutenir l'expansion du portefeuille R&D de l'entreprise.
Dr. Ratz rejoint Neurocrine après une carrière de 28 ans chez Eli Lilly, où il a contribué au développement et à l'enregistrement de plus de 25 produits dans plusieurs domaines thérapeutiques. Son rôle le plus récent était Vice-Président Senior et Responsable de la Distribution Médicamenteuse, des Dispositifs et des Solutions Connectées, où il a dirigé la conception intégrée des dispositifs, des produits combinés médicament-dispositif et des systèmes d'emballage. Auparavant, il avait été Directeur Senior de la Chimie des Procédés et de l'Ingénierie Chimique et Responsable de l'Externalisation Mondiale pour le portefeuille de petites molécules de Lilly.
Neurocrine Biosciences (NBIX) hat Andrew Ratz, Ph.D. zum Senior Vice President für Arzneimittelentwicklung, -lieferung und -geräte ernannt. Dr. Ratz wird die Transformation der Chemie-, Herstellungs- und Kontrollorganisation von Neurocrine leiten, um das wachsende F&E-Portfolio des Unternehmens zu unterstützen.
Dr. Ratz kommt zu Neurocrine nach 28 Jahren bei Eli Lilly, wo er an der Entwicklung und Zulassung von über 25 Produkten in mehreren therapeutischen Bereichen mitgewirkt hat. In seiner letzten Funktion war er Senior Vice President und Leiter der Arzneimittellieferung, Geräte und vernetzten Lösungen, wo er das integrierte Design von Geräten, Arzneimittel-Geräte-Kombinationsprodukten und Verpackungssystemen leitete. Zuvor war er Senior Director für Prozesschemie und chemische Verfahrenstechnik sowie Leiter des Global Outsourcing für Lilys Portfolio kleiner Moleküle.
- Appointment of seasoned executive with 28-year experience at Eli Lilly
- Track record of successful development and registration of 25+ products
- Expertise in drug delivery systems and device development strengthens R&D capabilities
- None.
Dr. Ratz joins Neurocrine after a 28-year career at Eli Lilly and Company, where he contributed to the development and successful registration of more than 25 products across multiple therapeutic areas and molecule modalities. Most recently, he served as Lilly's Senior Vice President and Head of the Drug Delivery, Device and Connected Solutions organization. He led the integrated design and development of devices, drug-device combination products, and packaging systems for both the biotech and small molecule portfolios. Prior to that, Dr. Ratz was Senior Director of Process Chemistry and Chemical Engineering and Head of Global Outsourcing for Lilly's small molecule portfolio.
"Andy brings unparalleled leadership and experience to Neurocrine's R&D team," Neurocrine Biosciences Chief Scientific Officer Jude Onyia, Ph.D., said. "He joins at a critical and exciting time for the company as we seek to discover and develop the next generation of treatments for patients with great needs."
"My love of science, coupled with a passion for helping people, has always driven my professional journey," Dr. Ratz said. "The opportunity to be part of Neurocrine, where innovation meets a commitment to improving lives, is truly inspiring. I am excited to contribute to the groundbreaking work being done here and to make a lasting impact on patients' lives through science and discovery."
Dr. Ratz received a Bachelor of Science degree in Chemistry from
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with
The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/andrew-ratz-phd-joins-neurocrine-biosciences-as-senior-vice-president-of-drug-development-delivery-and-device-302358103.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
What is Andrew Ratz's new role at Neurocrine Biosciences (NBIX)?
How many products did Andrew Ratz help develop at Eli Lilly before joining NBIX?
What was Andrew Ratz's most recent position before joining NBIX?
How will Andrew Ratz's appointment impact NBIX's R&D capabilities?
